Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

Voluntary Disclosure Announcement on the Approval of Marketing Application for New Indications of Xeligekimab

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Voluntary Disclosure Announcement on Approval of Marketing Application for New Indication of Xeligekimab

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis